特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959716

Seviteronel:新薬の洞察と市場予測 (2030年)

Seviteronel - Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
Seviteronel:新薬の洞察と市場予測 (2030年)
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Seviteronel(INO-464)は、CYP17リアーゼおよびAR (アンドロゲン受容体) の選択的阻害剤であり、前立腺がんや乳がんの治療に利用可能だと見込まれています。また、ARが引き起こす他のがん (卵巣がん・膀胱がん・肝臓がん・肺がんなど) や、性ステロイドの過剰生産が原因の非腫瘍性症候群 (子宮内膜症、多嚢胞性卵巣症候群、先天性副腎過形成、思春期早発症など) の治療への適用も期待されています。

当レポートでは、前立腺がん・乳がん等の治療薬であるSeviteronelの市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020~2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。

目次

第1章 医薬品の概要

  • 製品の詳細情報
  • 作用機序
  • 用法・用量
  • 研究開発 (R&D) 活動
    • 臨床開発
    • 安全性・有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国 (7MM) の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場参入企業

第6章 その他の新たな治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 SEVITERONEL, Description
  • Table 2 SEVITERONEL, Clinical Trial Description
  • Table 3 SEVITERONEL, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of SEVITERONEL
  • Figure 2 Patent Details, SEVITERONEL
  • Figure 3 SEVITERONEL, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 SEVITERONEL, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 SEVITERONEL, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 SEVITERONEL, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0067

"Seviteronel- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the Seviteronel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Seviteronel (INO-464) is a selective CYP17 lyase and AR inhibitor and the broad collection of multiple patented chemical classes of related compounds that were invented by scientists at Viamet Pharmaceuticals are wholly owned by Innocrin. Innocrin has identified high priority leads that have high CYP17 lyase potency and selectivity. It is Innocrina€s intent to leverage its organizational expertise to advance one or more of these 2nd-generation leads into clinical development. In addition to their potential use for the treatment of breast cancer and CRPC, inhibitors that target both CYP17 lyase and AR also have potential for the treatment of other cancers driven by the AR including ovarian, bladder, hepatocellular, and lung. Similarly, these inhibitors may also have commercial potential for the treatment of non-oncologic syndromes that are due to excess sex steroid production. These conditions include endometriosis, polycystic ovary syndrome, congenital adrenal hyperplasia, and precocious puberty, among others. Safety and convenience are important attributes of our product candidates.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around SEVITERONEL.
  • The report contains forecasted sales for SEVITERONEL till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prostate cancer.
  • The report also features the SWOT analysis with analyst insights and key findings of SEVITERONEL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Seviteronel Analytical Perspective by DelveInsight

  • In-depth Seviteronel Market Assessment

This report provides a detailed market assessment of Seviteronel in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • Seviteronel Clinical Assessment

The report provides the clinical trials information of Seviteronel covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Prostate cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Seviteronel dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Prostate cancer are giving market competition to SEVITERONEL and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SEVITERONEL.
  • Our in-depth analysis of the forecasted sales data of SEVITERONEL from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SEVITERONEL.

Key Questions:

  • Which company is developing SEVITERONEL along with the phase of the clinical study?
  • What is the technology utilized in the development of SEVITERONEL?
  • What is the product type, route of administration and mechanism of action of SEVITERONEL?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SEVITERONEL development?
  • What are the key designations that have been granted to SEVITERONEL?
  • What is the forecasted market scenario of SEVITERONEL?
  • What is the history of SEVITERONEL and what is its future?
  • What is the forecasted sales of SEVITERONEL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to SEVITERONEL?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.